Please wait a minute...
Reviews in Cardiovascular Medicine  2016, Vol. 17 Issue (S1): 9-21     DOI: 10.3909/ricm17S1S0002
Heat Failure University Previous articles | Next articles
Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management
Sandeep K. Krishnan, Norman E. Lepor
Cedars-Sinai Heart Institute, Los Angeles, CA
Download:  PDF(1001KB)  ( 23 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Hyperkalemia is a common electrolyte disorder associated with life-threatening cardiac arrhythmias and increased mortality. Patients at greatest risk for hyperkalemia include those with diabetes and those with impaired renal function in whom a defect in the excretion of renal potassium may already exist. Hyperkalemia is likely to become more common clinically because angiotensin receptor blockers and angiotensin-converting enzyme inhibitors are increasingly being used in higher doses and are thought to confer cardiovascular and renal protection. Until recently, options for treating hyperkalemia were limited to the use of thiazide and loop diuretics and sodium polystyrene sulfonate. Newer options such as sodium zirconium cyclosilicate will allow for the safe and effective treatment of hyperkalemia while maintaining patients on prescribed renin- angiotensin-aldosterone system inhibitors.
Key words:  Hyperkalemia      Potassium      Chronic kidney disease      Congestive heart failure      Patiromer      Sodium zirconium cyclosilicate     
Published:  20 January 2016     

Cite this article: 

Sandeep K. Krishnan, Norman E. Lepor. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management. Reviews in Cardiovascular Medicine, 2016, 17(S1): 9-21.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm17S1S0002     OR     https://rcm.imrpress.com/EN/Y2016/V17/IS1/9

[1] Meer Fakhry, Mandeep S. Sidhu, Sripal Bangalore, Roy O. Mathew. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 157-162.
[2] Anthony (Ming-yu) Chuang, Mau T Nguyen, Woon-Man Kung, Sam Lehman, Derek P Chew. High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 191-203.
[3] Chiara Minà, Laura Ajello, Gabriele Di Gesaro, Calogero Falletta, Francesco Clemenza. Hyperkalemia in heart failure: current treatment and new therapeutic perspectives[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 241-252.
[4] Michele Provenzano, Giuseppe Coppolino, Teresa Faga, Carlo Garofalo, Raffaele Serra, Michele Andreucci. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 209-220.
[5] Davide Bolignano, Anna Pisano, Graziella D’Arrigo. Pulmonary hypertension: a neglected risk condition in renal patients?[J]. Reviews in Cardiovascular Medicine, 2018, 19(4): 117-121.
[6] Sivakumar Sudhakaran, Teodoro Bottiglieri, Kristen M. Tecson, Aaron Y. Kluger, Peter A. McCullough. Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions[J]. Reviews in Cardiovascular Medicine, 2018, 19(3): 77-88.
[7] Peter A. McCullough, Aaron Y. Kluger, Kristen M. Tecson, Clay M. Barbin, Andy Y. Lee, Edgar V. Lerma, Zachary P. Rosol, Sivan L. Kluger, Janani Rangaswami. Inhibition of the Sodium–Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2[J]. Reviews in Cardiovascular Medicine, 2018, 19(2): 51-63.
[8] Claudio Ronco, Federico Ronco, Peter A. McCullough. A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine[J]. Reviews in Cardiovascular Medicine, 2017, 18(3): 93-99.
[9] Matthew M. Schumaecker, Timothy R. Larsen, , David C. Sane. Cardiac Manifestations of Adrenal Insufficiency[J]. Reviews in Cardiovascular Medicine, 2016, 17(3-4): 131-136.
[10] Peter A. McCullough, Maria Rosa Costanzo, Marc Silver, Bruce Spinowitz, Jun Zhang, Norman E. Lepor. Novel Agents for the Prevention and Management of Hyperkalemia[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 140-155.
[11] Peter McCullough, Rudolph A. de Boer, Frank Edelmann, Connie M. Lewis, Alan S. Maisel. Utilization of Galectin-3 in Case Management Across the Spectrum of Heart Failure[J]. Reviews in Cardiovascular Medicine, 2014, 15(3): 197-207.
[12] Stuart W. Rosenbush, Jeremy M. Parker. Height and Heart Disease[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 102-108.
[13] Peter A. McCullough, Thomas M. Beaver, Elliott Bennett-Guerrero, Michael Emmett, Gregg C. Fonarow, Abhinav Goyal, Charles A. Herzog, Mikhail Kosiborod, Biff F. Palmer. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management[J]. Reviews in Cardiovascular Medicine, 2014, 15(1): 11-23.
[14] Kasia J. Lipska, Mikhail Kosiborod. Management of Blood Glucose in Patients With Acute Coronary Syndromes[J]. Reviews in Cardiovascular Medicine, 2012, 13(2-3): 77-88.
[15] Alberto Palazzuoli, Matteo Beltrami, Savina Nodari, Peter A. McCullough, Claudio Ronco. Clinical Impact of Renal Dysfunction in Heart Failure[J]. Reviews in Cardiovascular Medicine, 2011, 12(4): 186-199.
No Suggested Reading articles found!